Association of High-Density Lipoprotein Cholesterol Levels with Outcomes in Non-Ischemic Dilated Cardiomyopathy
Overview
This study investigates the relationship between high-density lipoprotein cholesterol (HDL-C) levels and clinical outcomes in patients with non-ischemic dilated cardiomyopathy (DCM).
Background
Non-ischemic dilated cardiomyopathy is a significant cause of heart failure, characterized by left ventricular dilation and systolic dysfunction without coronary artery disease. Identifying reliable prognostic biomarkers is crucial for improving risk stratification in this heterogeneous patient population. HDL-C has been linked to cardiovascular outcomes, yet its specific prognostic role in DCM remains unclear.
Data Highlights
Endpoint
Event Rate
Hazard Ratio (HR)
95% Confidence Interval (CI)
P-value
Primary (all-cause mortality and heart transplantation)
41 (13.8%)
0.19
0.05–0.68
0.011
Secondary (including heart failure readmission)
97 (32.7%)
0.15
0.07–0.34
<0.001
Key Findings
Lower HDL-C levels are associated with adverse outcomes in patients with non-ischemic DCM.
Multivariable Cox regression models indicate a significant hazard ratio for lower HDL-C regarding mortality and heart transplantation.
The association between HDL-C and clinical outcomes is partially attenuated by adjusting for pulmonary hypertension markers.
RCS curves demonstrate a linear relationship between HDL-C levels and clinical outcomes.
Clinical Implications
Clinicians should consider HDL-C levels when assessing long-term outcomes in this patient population.
Conclusion
Lower HDL-C levels are linked to worse clinical outcomes in non-ischemic DCM.
